Date: 2018-08-01
Type of information: Nomination
Compound: member of the board of directors
Company: Celyad (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 1, 2018, Celyad announced that Dr. Margo Roberts is joining Celyad’s Board of Director and its scientific committee. Dr. Margo Roberts served as Chief Scientific Officer at Kite Pharma (acquired by Gilead in October 2017) starting in 2013, where she built a talented research organization that played an instrumental role in the successful development of Yescarta®, and the clinical advancement of additional CAR/TCR-engineered T-cell therapies. Most recently, Dr. Roberts served as Senior Vice President of Discovery Research at Kite Pharma focusing on the development of next generation therapeutic approaches, including heading up Kite’s universal allogeneic T-cell programs.
- Dr. Roberts has almost three decades of biomedical research experience in both biotechnology and academia. Prior to her tenure at Kite Pharma, Dr. Roberts was Principal Scientist and Director of Immune and Cell Therapy at Cell Genesys, Inc., where she led the development and application of CAR technology to T-cells and stem cells, culminating in the very first CAR T-cell trial initiated in 1994. Dr. Roberts was also an associate professor at the University of Virginia, has authored over thirty scientific publications, and is the inventor on thirteen issued US patents and three published US patent applications related to CAR technology and tumor vaccine therapies. Dr. Roberts received both her Bachelor of Science degree with honors and her Ph.D. degree from the University of Leeds in England. Dr. Roberts’ appointment at Celyad’s Board is effective immediately.
Financial terms:
Latest news:
Is general: Yes
